
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study
The Lancet Neurology
Fecha de publicación: Setiembre de 2021
Autores: Elisabeth H Thijssen, MSc *, Renaud La Joie, PhD *, Amelia Strom, BS, Corrina Fonseca, BS, Leonardo Iaccarino, PhD, Amy Wolf, BS, Salvatore Spina, MD, Prof Isabel E Allen, PhD, Yann Cobigo, PhD, Hilary Heuer, PhD, Lawren VandeVrede, MD, Nicholas K Proctor, BS, Argentina Lario Lago, PhD, Suzanne Baker, PhD, Rajeev Sivasankaran, PhD, Agnieszka Kieloch, Arvind Kinhikar, PhD, Lili Yu, Marie-Anne Valentin, PhD, Andreas Jeromin, PhD, Prof Henrik Zetterberg, MD, Prof Oskar Hansson, MD, Niklas Mattsson-Carlgren, MD, Danielle Graham, PhD, Prof Kaj Blennow, MD, Prof Joel H Kramer, PsyD, Lea T Grinberg, MD, Prof William W Seeley, MD,Prof Howard Rosen, MD, Prof Bradley F Boeve, MD, Prof Bruce L Miller, MD, Prof Charlotte E Teunissen, PhD, Prof Gil D Rabinovici, MD, Julio C Rojas, MD, Jeffrey L Dage, PhD
DOI: https://doi.org/10.1016/S1474-4422(21)00214-3
Background: Plasma tau phosphorylated at threonine 217 (p-tau217) and plasma tau phosphorylated at threonine 181 (p-tau181) are associated with Alzheimer’s disease tau pathology. We compared the diagnostic value of both biomarkers in cognitively unimpaired participants and patients with a clinical diagnosis of mild cognitive impairment, Alzheimer’s disease syndromes, or frontotemporal lobar degeneration (FTLD) syndromes.